Loading
Immunotherapy and Immune Responses / Vaccines and Immunoinformatics Approaches / Polyomavirus and Related Diseases · Journal article
The Journal of Immunology · July 28, 2026
Early or partial results. Treat as a signal, not a conclusion.
This systematic epitope discovery study identified MCPyV-derived peptides presented across diverse HLA-I alleles with measurable T cell reactivity in both VP-MCC patients and healthy controls, supporting the feasibility of an off-the-shelf therapeutic vaccine. The work establishes a methodological framework and target candidates but does not provide clinical efficacy, safety, or immunogenicity data from a human trial.
Epitope discovery study combining HLA-I immunoprecipitation, mass spectrometry, in silico prediction, and functional immunological validation. VP-MCC patients and HLA-matched healthy blood donors; patient-derived VP-MCC cell lines. Intervention: Systematic epitope identification and validation of MCPyV-derived peptide candidates for vaccine development.
MCPyV-derived epitopes identified with presentation across diverse HLA-I alleles Conserved and promiscuous peptides demonstrated measurable T cell reactivity in both VP-MCC patients and healthy donors MCPyV immunopeptidome expanded across a dozen patient-derived VP-MCC cell lines to enable functional T cell targeting evaluation
ELISpot assays are surrogate endpoints; no clinical outcomes, tumor response rates, or safety data provided
This work identifies candidate epitopes and validates a discovery framework for MCC vaccine development, but does not yet establish immunogenicity or efficacy in human subjects. Clinicians should view this as a preclinical proof-of-concept that warrants progression to Phase 1 clinical testing.
This is an epitope discovery and validation study using in vitro immunological assays and patient-derived models, establishing feasibility for vaccine development but lacking clinical efficacy data or Phase trial results.
As stated by the source record.
Quoted from the source exactly as published.
This work identifies candidate epitopes and validates a discovery framework for MCC vaccine development, but does not yet establish immunogenicity or efficacy in human subjects. Clinicians should view this as a preclinical proof-of-concept that warrants progression to Phase 1 clinical testing.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Introduction Merkel cell carcinoma (MCC) is a rare but extremely aggressive neuroendocrine skin cancer with a two-year mortality approaching 20% in patients with distant metastasis, representing a significant unmet clinical need. More than 80% of MCC cases are driven by Merkel cell polyomavirus (MCPyV), whose antigens are foreign to the immune system, highly immunogenic, and correlate with survival and response to immunotherapy. The uniform expression of its oncoprotein makes a virus-positive MCC (VP-MCC) an ideal target for antigen-specific immunotherapies. Methods We systematically defined MCPyV-derived epitopes presented by HLA-I molecules to identify suitable targets for development of a universal off-the-shelf vaccine. An integrated discovery pipeline was developed combining HLA-I pull-downs and LC—MS/MS-based detection using a panel of 95 monoallelic HLA lines, in silico antigen prediction, and literature curation. Immunogenicity of candidates was evaluated using VP-MCC patients and HLA-matched healthy PBMCs, with ELISpot assays as the primary readout. To enable functional validation, the MCPyV immunopeptidome was expanded to a dozen patient-derived VP-MCC cell lines, providing a platform to examine T cell targeting. Results This approach enabled the identification of MCPyV-derived epitopes presented across diverse HLA-I alleles, including conserved and promiscuous peptides with measurable T cell reactivity in both patients and healthy donors. Expansion of the MCPyV immunopeptidome across patient-derived MCC models supported downstream functional evaluation of antigen-specific T cell responses in physiologically relevant tumor contexts. Conclusion Our findings define a roadmap for MCPyV antigen selection and support the feasibility of developing an off-the-shelf therapeutic vaccine for VP-MCC. More broadly, this systematic framework for epitope discovery and validation may be broadly applicable to immunotherapy development in other virally driven cancers. Funding Source NIH, SNSF Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.